BASELINE HBSAG LEVELS PREDICT HBSAG LOSS IN HBEAG NEGATIVE BUT NOT IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA): AN INTERIM ANALYSIS

被引：0
|
作者：
Takkenberg, Bart [1 ,2 ]
Zaaijer, Hans L. [3 ,4 ]
de Niet, Annikki [1 ,2 ]
Weegink, Christine J. [1 ,2 ]
Terpstra, Valeska [5 ]
Koot, Maarten [7 ]
Dijkgraaf, Marcel [6 ]
Jansen, Peter L. [1 ,2 ]
Janssen, Harry L. [8 ]
Beld, Marcel [9 ]
Reesink, Hendrik W. [1 ,2 ]
机构：
[1] AMC Liver Ctr, Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Med Microbiol & Karl Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands
[4] Ctr Infect Dis & Immunol CINIMA, Amsterdam, Netherlands
[5] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands
[6] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[7] Sanquin, Dept Virus Diagnost Serv, Amsterdam, Netherlands
[8] Erasmus MC, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands
[9] KIT Biomed Res, Amsterdam, Netherlands
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
488
引用
收藏
页码：536A / 537A
页数：2
相关论文
共 50 条
  • [31] HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Mimidis, K.
    Germanidis, G.
    Triantos, C.
    Drakoulis, C.
    Chounta, A.
    Tsoplou, F.
    Zintzaras, E.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S201 - S202
  • [32] Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    Lau, GKK
    Piratvisuth, T
    Luo, KX
    Marcellin, P
    Thongsawat, S
    Cooksley, G
    Gane, E
    Fried, MW
    Chow, WC
    Paik, SW
    Chang, WY
    Berg, T
    Flisiak, R
    McCloud, P
    Pluck, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26): : 2682 - 2695
  • [33] Asian patients with HBeAg-negative chronic hepatitis B respond well to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment
    Jia, Ji-Dong
    Piratvisuth, Teerha
    Lau, George K. K.
    Luo, Kang-Xian
    Jin, Rui
    Lu, Zhi-Meng
    Marcellin, Patrick
    Popescu, Matei
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A88 - A88
  • [34] A practical tool to predict response to peginterferon alfa-2a in Asian patients with HBeAg-positive chronic hepatitis B
    Chow, Wan Cheng
    Cooksley, Graham
    Piratvisuth, Teerha
    Lau, George Kk
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A32 - A32
  • [35] HBcrAg levels at baseline are not predictive for HBsAg and HBeAg loss in patients treated with adefovir and PEG-interferon
    Erken, Robin
    Zaaijer, Hans
    Bakker, Ed
    Kootstra, Neeltje
    Reesink, Henk
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E256 - E256
  • [36] Predictors of histologic improvement and relationship between sustained response and histology in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) (PEGASYS®)
    Lau, GK
    Cooksley, G
    Marcellin, P
    Piratvisuth, T
    Hadziyannis, S
    Farci, P
    Fried, MW
    Bonino, F
    Jin, R
    Button, P
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 587A - 587A
  • [37] Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase
    Chen, Li
    Shi, Junjie
    Lu, Zhonghua
    Ye, Yun
    Zhou, Xinbei
    Tan, Youwen
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (03) : 310 - 316
  • [38] Evidence for the efficacy of peginterferon alfa-2a (40 KD) (pegasys) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors
    Cooksley, WGE
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, FE
    Pluck, N
    JOURNAL OF HEPATOLOGY, 2002, 36 : 8 - 8
  • [39] Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-positive chronic hepatitis B
    Xu, D. -Z.
    Xie, Y.
    Wei, L.
    Chen, X. Y.
    Wan, M. -B.
    Wang, Y. -M.
    Wang, L.
    Wei, J.
    Gan, J. -H.
    Tian, D. -Y.
    Zhang, S. -L.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S266 - S266
  • [40] KINETICS OF HBSAG DECLINE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A ACCORDING TO GENOTYPE AND ITS ASSOCIATION WITH SUSTAINED HBSAG CLEARANCE 4 YEARS POST-TREATMENT
    Brunetto, Mourizia
    Bonino, Ferruccio
    Marcellin, Patrick
    Button, Peter
    Batrla, Richard
    HEPATOLOGY, 2008, 48 (04) : 740A - 740A
12345